Human Endotoxemia as a model of systemic inflammation

被引:231
作者
Andreasen, A. S. [1 ,2 ]
Krabbe, K. S. [1 ,2 ]
Krogh-Madsen, R. [1 ,2 ]
Taudorf, S. [1 ,2 ]
Pedersen, B. K. [1 ,2 ]
Moller, K. [1 ,2 ,3 ]
机构
[1] Univ Copenhagen, Ctr Inflammat & Metab, Dept Infect Dis, DK-1168 Copenhagen, Denmark
[2] Univ Copenhagen, Copenhagen Muscle Res Ctr, DK-1168 Copenhagen, Denmark
[3] Univ Copenhagen, Fac Hlth Sci, Rigshosp, Univ Hosp,Intens Care Unit 4131, DK-1168 Copenhagen, Denmark
关键词
cytokine; diabetes; endotoxin; inflammation; LPS; interleukin-6; sepsis; tumor necrosis factor-alpha;
D O I
10.2174/092986708784872393
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimer's disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ- specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human- experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model.
引用
收藏
页码:1697 / 1705
页数:9
相关论文
共 151 条
[1]   STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS [J].
ADERKA, D ;
ENGELMANN, H ;
MAOR, Y ;
BRAKEBUSCH, C ;
WALLACH, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :323-329
[2]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[3]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[4]   Current epidemiology of septic shock - The CUB-Rea network [J].
Annane, D ;
Aegerter, P ;
Jars-Guincestre, MC ;
Guidet, B .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (02) :165-172
[5]   TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].
Arbour, NC ;
Lorenz, E ;
Schutte, BC ;
Zabner, J ;
Kline, JN ;
Jones, M ;
Frees, K ;
Watt, JL ;
Schwartz, DA .
NATURE GENETICS, 2000, 25 (02) :187-+
[6]  
BALIS JU, 1978, LAB INVEST, V38, P511
[7]   INFLUENCE OF HYPERCORTISOLEMIA ON SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II AND INTERLEUKIN-1 RECEPTOR ANTAGONIST RESPONSES TO ENDOTOXIN IN HUMAN-BEINGS [J].
BARBER, AE ;
COYLE, SM ;
FISCHER, E ;
SMITH, C ;
VANDERPOLL, T ;
SHIRES, T ;
LOWRY, SF .
SURGERY, 1995, 118 (02) :406-411
[8]   Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro [J].
Bastard, JP ;
Maachi, M ;
Van Nhieu, JT ;
Jardel, C ;
Bruckert, E ;
Grimaldi, A ;
Robert, JJ ;
Capeau, J ;
Hainque, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) :2084-2089
[9]   Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation [J].
Bethin, KE ;
Vogt, SK ;
Muglia, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9317-9322
[10]   Innate immune sensing and its roots: the story of endotoxin [J].
Beutler, B ;
Rietschel, ET .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (02) :169-176